SCHEMBL11900542

SCHEMBL11900542

O=C(O)c1c(F)ccc([N+](=O)[O-])c1NC1CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 3/20 0.50
MAPT P10636 5/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
HTT P42858 2/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
CASP6 P55212 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11901389 0.85 HCAR3 (0.41) HCAR3MAPTGLAGAAALDH1A1
SCHEMBL20337755 0.81 MAPT (0.47) HCAR3MAPTGLAGAAALDH1A1
SCHEMBL11901649 0.76 MEN1 (0.50) HCAR3MAPTGAAALDH1A1MAPK1
SCHEMBL21749965 0.75 TDP1 (0.51) HCAR3MAPTALDH1A1L3MBTL1HTT
SCHEMBL2507487 0.75 MAPT (0.44) HCAR3MAPTGLAGAAALDH1A1
SCHEMBL2503345 0.74 TSHR (0.53) HCAR3MAPTGAAALDH1A1L3MBTL1
SCHEMBL633629 0.74 TDP1 (0.46) MAPTALDH1A1L3MBTL1HTTMEN1
SCHEMBL25220217 0.72 TDP1 (0.42) HCAR3MAPTGLAGAAALDH1A1
SCHEMBL29154301 0.72 TDP1 (0.45) MAPTALDH1A1L3MBTL1HTTMEN1
SCHEMBL14249826 0.72 GSK3A (0.45) HCAR3MAPTGLAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 HCAR3 1669/4885MAPT 1752/4885GLA 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.